Ysios Capital
Ysios Capital is a leading life sciences investor focused on financing highly innovative biotech companies worldwide. The firm provides resources to develop novel therapies for indications with high unmet medical needs, aiming to have a positive impact on patients and society. With a global outlook and proven performance, Ysios Capital manages over €400 million in assets and has invested in 40 companies, bringing 19 products to market and having over 70 products at the clinical stage.
Ysios Capital
What We Do
Ysios Capital provides financial resources to biotech ventures to develop novel therapies.
The firm offers strategic guidance to its portfolio companies, leveraging its team's scientific, financial, and entrepreneurial expertise.
Ysios Capital provides mentorship to new and promising companies, helping them achieve success.
The firm connects its portfolio companies with a network of industry experts and potential partners.
Geographic Focus
Portfolio
Adcendo is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (ADCs).
#Biotechnology
Anaconda Biomed is among the world’s most innovative early-stage medical technology companies.
#Medical Technology
Aura Biosciences is applying nanotechnology to the fight against cancer with its novel viral nanoparticle technology.
#Biotechnology
BioVex was focused on the development and commercialization of biological treatments for cancer and infectious disease using oncolytic viruses.
#Biotechnology
CorWave is developing next-generation blood pumps for heart failure patients.
#Medical Technology
Cytoki Pharma is engaged in the development of protein drugs for diseases characterized by epithelial injury.
#Biotechnology
EndoSense was focused on improving the efficacy, safety, and reproducibility of catheter ablation for cardiac arrhythmias.
#Medical Technology
Engrail is a clinical-stage pharmaceutical company aspiring to become a leader in neuroscience.
#Pharmaceuticals
Fusion Pharmaceuticals develops next-generation radiopharmaceuticals for precision medicine.
#Pharmaceuticals
KALA BIO is developing treatments for rare ophthalmic diseases using its MSC-S platform.
#Biotechnology
Kynexis is developing a novel drug to treat cognitive impairment in patients with schizophrenia.
#Biotechnology
LAVA Therapeutics is developing a bispecific antibody platform for treating hematological and solid cancers.
#Biotechnology
Memo is developing best-in-class therapeutic antibodies for virus infections and cancer.
#Biotechnology
Mineralys Therapeutics is developing novel therapy for hypertension.
#Biopharmaceuticals
Minoryx is developing new therapies for orphan CNS diseases with a high unmet medical need.
#Biotechnology
Neurona is developing regenerative cell therapies for the nervous system.
#Biotherapeutics
NorthSea Therapeutics is developing therapeutic strategies for NASH and other metabolic diseases.
#Biotechnology
Ona Therapeutics specializes in therapeutic biologics targeting tumor metastatic-initiating cells.
#Biotechnology
Sanifit is focused on developing SNF472 for cardiovascular diseases linked to calcification.
#Biopharmaceuticals
SparingVision is focused on therapies for blinding inherited retinal diseases.
#Biotechnology
Splice Bio is developing gene therapies based on its intein platform technology.
#Gene Therapy
STAT-DX developed near-patient testing products for healthcare professionals.
#Medical Technology
Synendos is developing small molecules for the endocannabinoid system in the brain.
#Biopharmaceuticals
Tagworks is developing click cleavable therapeutics for oncology.
#Pharmaceuticals
TiGenix developed treatments based on cell therapy and was acquired by Takeda Pharmaceuticals.
#Biopharmaceuticals
VarmX is developing therapeutic proteins for bleeding prevention and treatment.
#Pharmaceuticals
Vivet Therapeutics is developing gene therapy treatments for orphan diseases.
#Gene Therapy